Blog | HemaCare

Engineering T Cells to Target Senescence for Improved Therapeutic Options

Sep 22, 2020 10:03:00 AM / by Stacy Matthews Branch, DVM, PhD posted in CAR-T, T Cells


Researchers have found that T Cells can target cells that are in a state of cellular senescence, without damaging the tissues while promoting a longer life span. 

When a cell is in a state of cycle arrest and is stable in that cycle, it is considered cellular senescence. Senescent cells do not respond to growth-promoting signaling or stimuli and exhibit various biochemical changes leading to a phenotype characterized by altered gene expression and changes in cellular metabolism. The biological role of senescence is multifaceted and is important during embryonic development and wound healing. However, it is also involved in pathological processes such as cancer development and chronic inflammatory conditions.

Read More

HemaCare PBMCs Provide Vital Data for CAR T Cell Primate Study

Aug 25, 2020 10:04:00 AM / by Nancy Andon, MSc posted in CAR-T, PBMCs


A recent collaborative study published by Amgen and Kite Pharma cites the use of HemaCare sourced peripheral blood mononuclear cells (PBMC) in their investigative effort on the development of a novel CAR T cell therapy. [1]

Acute myeloid leukemia (AML) is a form of blood cancer characterized by the rapid buildup of abnormal cells in the bone marrow. The disease affects about a million people globally and, tragically, has a less than 30% survival rate.

Read More

Exploring CAR-T and TCR-T Therapies for COVID-19 Treatment

Jun 16, 2020 10:09:00 AM / by Stacy Matthews Branch, DVM, PhD posted in CAR-T, Cell Therapy, T Cells


As the fight against COVID-19 continues, the use of CAR-T or TCR-T therapies may be able to help treat patients infected, but more research is needed.

The last decade of research has provided significant advances in anti-cancer immunotherapies. Particularly, the development of genetically modified T-cells has been successful in treating various types of cancers. Chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy are major examples of highly studied immunotherapies. CAR-T cells recognize proteins or antigens expressed on the surface of cancer cells, whereas TCR-T cells recognize tumor antigens inside the cells.

Read More

Could Immunotherapy Effectively Treat Diseases Other Than Cancer

Feb 18, 2020 10:02:00 AM / by Stacy Matthews Branch, DVM, PhD posted in CAR-T, Immunotherapy (Immunology)


Traditionally used to treat cancer, new research shows how immunotherapy could also be useful for treating other diseases as well.

The goal of immunotherapy is to modify or influence the immune system in such a way to enhance its disease-fighting ability. Immunotherapies have been extensively studied and developed for the treatment of various forms of cancer. One type of immunotherapy used to target cancer cells is chimeric antigen receptor T (CAR-T) cell therapy.  In CAR-T therapy, a patient’s T cells are harvested, genetically engineered to target cancer cells, and grown under laboratory conditions. These cells are then injected back into the patient. There are a number of research endeavors that are now investigating the effectiveness of CAR-T cells for non-cancer diseases, including autoimmune conditions.

Read More

CAR T Cell Drug Touts Long-Term Survival Rates

Dec 17, 2019 10:00:00 AM / by Nancy Andon, MSc posted in CAR-T, Cell Therapy, T Cells


CAR T cell therapy has been one of the most exciting medical advances of this decade. As a type of immunotherapy, CAR T treatment consists of collecting patient-derived immune T cells, and genetically engineering them to recognize and fight invasive cancer cells. The first of these therapies to receive U.S. Food and Drug Administration (FDA) approval, Novartis’ Kymriah®, and Gilead’s Yescarta® garnered international attention for their astonishing success rates in clinical trial.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts